Phaseline

Companies › 858 Therapeutics

858 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ETX-19477
PARG inhibitor
PARGPhase 1Advanced or Metastatic Solid TumorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06395519ETX-19477Phase 1Advanced or Metastatic Solid TumorsOncologyDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

PARG (1)

Companies with the same targets

FoRx Therapeutics Evopoint Biosciences IDEAYA Biosciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.